Roundup Litigation (Bayer/Monsanto): > $18B Mass Tort

Tens of thousands of US plaintiffs allege that glyphosate-based Roundup causes non-Hodgkin lymphoma. Bayer, which inherited the litigation through its $63B Monsanto acquisition, has committed more than $18B to resolving it, and in 2026 secured both a Supreme Court preemption win and a $7.25B class settlement that could finally cap the decade-old litigation.

LATEST DEVELOPMENT · JUN 25, 2026

On June 30, 2026, the Missouri Circuit Court judge overseeing Bayer’s $7.25B nationwide NHL class settlement rescheduled the final fairness hearing from July 9 to August 19, 2026. Objecting class members have appealed the June 17, 2026 federal remand order to the Eighth Circuit, and on July 1-2, 2026 Bayer announced it is consolidating its U.S. glyphosate business into a new subsidiary, Ruveon LLC, based in St. Louis, following the Supreme Court’s June 25, 2026 preemption ruling in Monsanto v. Durnell.

PREDICTED OUTCOME

AI-GENERATED · METHODOLOGY →

Settlement ~70% likely HORIZON: approval by early 2027 CONFIDENCE: MEDIUM

The most likely endgame, at roughly 70 percent, is final approval of the $7.25 billion nationwide NHL class settlement in Judge Boyer’s court within weeks of the August 19, 2026 fairness hearing, followed by two years of objector appeals that leave the deal substantially intact by mid to late 2028. The driver is asymmetric incentive alignment after Durnell: Bayer now holds a preemption shield on the label theory but still faces design-defect and negligence exposure plus $2 billion punitive verdicts like Barnes, so a capped, 21-year funded program at roughly $6,000 to $165,000 per claimant is cheaper and more predictable than another decade of jury roulette, while plaintiffs’ leadership knows Durnell just gutted the theory behind most of their signature judgments. Expect Bayer’s total committed spend to settle in the $18 billion to $22 billion range once the earlier $10.9 billion framework, the final $611 million Cole County judgment with interest, and opt-out resolutions are counted. The Eighth Circuit CAFA appeal of the June 17 remand is the main procedural wildcard, but remand appeals of this type rarely produce case-restructuring relief fast enough to derail a state-court approval already in motion. The Ruveon LLC carve-out is best read as insurance: a ring-fenced vehicle that preserves a Texas-two-step style bankruptcy option if approval fails or is reversed. The leading alternative, at about 20 percent, is that the future-claims settlement class is rejected or vacated on adequacy and predominance grounds, pushing Bayer toward a Ruveon Chapter 11 or a narrower claim-by-claim wind-down under the Durnell shield. Straight claimant victory on the merits across the remaining inventory is now the least plausible path, since the surviving non-label theories have a much weaker verdict record.

Preliminary approval granted; fairness hearing set August 19, 2026 · Durnell 7-2 preemption win strips plaintiffs’ core failure-to-warn theory · Bayer needs finality and capped, long-dated funding for balance sheet · Ruveon carve-out preserves credible bankruptcy threat against objectors · Future-claims settlement class vulnerable on adequacy in appellate review

Generated by claude-opus-5 on Aug 4, 2026, from this case’s record only. It stands until a major development changes the record. Not legal or investment advice. How predictions are made →

BACKGROUND

The litigation exploded after IARC classified glyphosate as ‘probably carcinogenic’ in 2015. A string of nine-figure and ten-figure jury verdicts, Johnson ($289M, 2018), Hardeman, and Pilliod ($2B, 2019), pushed Bayer into a roughly $10.9B settlement framework in 2020, but tens of thousands of claims were never resolved and new cases continue to be filed.

Bayer’s core legal strategy is federal preemption: that FIFRA’s federal labeling regime bars state-law failure-to-warn claims. The Third Circuit accepted a version of that argument in 2024, deepening a circuit split, and in June 2026 the Supreme Court resolved the question in Monsanto’s favor in Monsanto v. Durnell, even as juries continued to deliver eye-watering verdicts, including $2.1B in Georgia in March 2025. A $7.25B nationwide class settlement announced in February 2026 awaits final approval.

TIMELINE

JUL 1, 2026OTHER

Bayer consolidates U.S. glyphosate business into new entity Ruveon LLC

Bayer announced it is restructuring its U.S. glyphosate business, including Roundup, into a new St. Louis-based subsidiary called Ruveon LLC, led by CEO Alfonso Alba Ordonez, as part of its broader response to the Roundup litigation landscape following the Supreme Court’s Durnell ruling.

Bayer Group to consolidate U.S. glyphosate business into distinct entity operating as Ruveon Bayer Consolidates U.S. Glyphosate Business Into New Entity Ruveon LLC
JUN 30, 2026PROCEDURAL

Missouri court reschedules Roundup class settlement fairness hearing to August 19, 2026

Judge Boyer of the Missouri Circuit Court moved the final approval hearing for Bayer’s $7.25B nationwide NHL class settlement from its original July 9, 2026 date to August 19, 2026, while keeping the June 2026 opt-out deadline unchanged.

Managing the Roundup™ Litigation Roundup Settlement 2026: $7.25 Billion Bayer Payout
JUN 25, 2026JUDGMENT

Supreme Court holds FIFRA preempts Roundup failure-to-warn claims (7-2)

Justice Kavanaugh’s majority in Monsanto v. Durnell reversed a Missouri failure-to-warn judgment. Justice Jackson, joined by Justice Gorsuch, dissented. Design-defect, negligence and other non-label theories survive.
JUN 2026APPEAL

Objecting class members appeal remand order to Eighth Circuit

After a federal judge remanded the class settlement dispute (King v. Monsanto) back to Missouri state court on June 17, 2026, the objecting plaintiffs appealed that remand decision to the Eighth U.S. Circuit Court of Appeals.

Judge Remands $7.25B Bayer Roundup Settlement
MAR 4, 2026PROCEDURAL

Missouri court grants preliminary approval of the class settlement

Opt-out deadline June 4, 2026. Objectors briefly removed the case to federal court. It was remanded to Missouri state court in June 2026, with final approval proceedings continuing.
FEB 17, 2026SETTLEMENT

Monsanto announces $7.25B nationwide class settlement

Designed to resolve current and future non-Hodgkin lymphoma claims through a long-term claims program funded over up to 21 years, with individual payouts reported at roughly $6,000–$165,000.
JAN 16, 2026APPEAL

US Supreme Court grants certiorari in Monsanto v. Durnell

Question presented: whether FIFRA preempts a label-based failure-to-warn claim where EPA has not required the warning. Argued April 27, 2026.
SEP 30, 2025APPEAL

Missouri Supreme Court declines review of reduced $611M Cole County judgment

The October 2023 $1.56B verdict for four plaintiffs, cut to $611M and affirmed by the Western District Court of Appeals in May 2025, became final, worth over $700M with interest.
MAR 21, 2025JUDGMENT

Georgia jury awards $2.1B in Barnes v. Monsanto

$65M compensatory plus $2B punitive after a three-week trial in Cobb County State Court. Monsanto vowed to appeal.
AUG 15, 2024APPEAL

Third Circuit rules for Monsanto on FIFRA preemption (Schaffner)

Created a deeper circuit split on whether federal law preempts state failure-to-warn claims.
JUN 21, 2022APPEAL

US Supreme Court declines to hear Hardeman preemption appeal
JUN 24, 2020SETTLEMENT

Bayer announces ~$10.9B settlement framework
MAY 13, 2019JUDGMENT

Pilliod verdict: $2B (later reduced)
AUG 10, 2018JUDGMENT

Johnson v. Monsanto: first trial ends in $289M verdict

Later reduced, but it opened the floodgates.